Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial. Mutter RW, Giri S, Fruth BF, Remmes NB, et al. Lancet Oncol 2023;24:1083-1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mutter RW, Giri S, Fruth BF, Remmes NB, et al. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial. Lancet Oncol 2023;24:1083-1093.
PMID: 37696281